Notice of Results

By

Regulatory News | 27 Aug, 2020

Updated : 12:01

RNS Number : 3562X
Clinigen Group plc
27 August 2020
 

27 August 2020

 

Clinigen Group plc 

 

Notification of full year results date

 

Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2020 on Thursday 17 September 2020.

 

The analyst meeting will be held virtually at 9.30am. Analysts should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register their interest.

 

-Ends-

 

 

For further information, please contact:

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

 

Nick Keher, Group Chief Financial Officer

 

Matt Parrish, Head of Investor Relations

 

 

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Broker

Tel: +44 (0)20 7742 4000

James Mitford / Hemant Kapoor

 

 

 

RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

 

 

 

Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage

Email: clinigen@instinctif.com

 

Notes to Editors

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

 

For more information on Clinigen, please visit http://www.clinigengroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBDLFLBVLEBBB

Last news